鹭燕医药(002788) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥4,750,914,303.02, a decrease of 4.66% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥72,962,256.96, down 11.12% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.19, a decrease of 9.52% compared to the same period last year[5] - Total operating revenue for the current period reached ¥14,775,163,931.09, an increase of 3.16% compared to ¥14,323,765,912.83 in the previous period[21] - Total operating costs amounted to ¥14,436,462,358.36, up from ¥13,967,712,770.29, reflecting a year-over-year increase of 3.36%[21] - Net profit for the current period was ¥259,059,315.29, representing a 2.4% increase from ¥251,958,323.00 in the previous period[22] - The company reported a total profit of ¥322,741,032.04, slightly down from ¥332,785,948.04 in the previous period[22] Cash Flow and Assets - The net cash flow from operating activities increased by 704.58% year-to-date, reaching ¥741,459,736.05, attributed to improved accounts receivable management and new financing tools[8] - The net cash flow from operating activities was ¥741,459,736.05, significantly higher than ¥92,154,381.20 in the previous period[24] - Cash and cash equivalents at the end of the period totaled ¥445,463,828.70, compared to ¥286,140,227.71 at the end of the previous period[25] - The company's cash and cash equivalents stood at CNY 589,295,901.31 as of September 30, 2023, slightly down from CNY 594,189,831.11 at the beginning of the year[18] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥11,421,596,888.22, a decrease of 3.07% from the end of the previous year[5] - The company's total liabilities as of September 30, 2023, were CNY 8,539,977,837.96, down from CNY 8,993,147,283.00 at the start of the year[19] - The total equity attributable to the parent company increased to CNY 2,850,343,543.74 from CNY 2,720,812,852.98 at the beginning of the year, reflecting a growth of approximately 4.77%[19] - Accounts receivable decreased to CNY 5,721,291,504.99 from CNY 5,837,079,391.23, indicating a reduction of about 1.99%[18] - Inventory levels decreased to CNY 2,256,781,668.15 from CNY 2,548,589,433.26, representing a decline of approximately 11.45%[18] - The company reported a total of CNY 1,894,210,612.79 in accounts payable, down from CNY 2,270,403,681.48, reflecting a decrease of approximately 16.56%[19] Shareholder Information - The company reported a total of 25,463 common shareholders at the end of the reporting period[10] - The company's equity attributable to shareholders increased by 4.76% year-on-year, amounting to ¥2,850,343,543.74[5] Legal and Regulatory Matters - The company has initiated legal actions to recover CNY 3,969.73 million in damages from related parties, with a recent court ruling awarding CNY 3,162.83 million plus interest[16] - The company received government subsidies amounting to ¥1,988,917.97 during the reporting period[6] - The company has not identified any other non-recurring profit and loss items beyond those reported[7] Strategic Initiatives - The company is actively exploring new financing tools such as supply chain financing and factoring[8] - The company has implemented new accounting standards starting from 2023[26] - The third quarter report of Luyuan Pharmaceutical Co., Ltd. is unaudited[26] - There are no specific financial performance metrics or user data provided in the document[26] - Future outlook and performance guidance are not detailed in the document[26] - Information regarding new products or technologies is not mentioned[26] - Market expansion and mergers or acquisitions are not discussed in the document[26] - Other strategic initiatives are not outlined in the content[26] - The document does not provide any numerical data or percentages related to financial performance[26] - The report does not include any audited financial statements[26]